Last reviewed · How we verify
Comparator: sumatriptan
Sumatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches.
Sumatriptan is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. Used for Acute migraine with or without aura, Cluster headache.
At a glance
| Generic name | Comparator: sumatriptan |
|---|---|
| Also known as | sumatriptan |
| Sponsor | Organon and Co |
| Drug class | Triptan (5-HT1B/1D receptor agonist) |
| Target | 5-HT1B receptor, 5-HT1D receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Sumatriptan binds to 5-HT1B receptors on cranial blood vessels causing vasoconstriction, and to 5-HT1D receptors on trigeminal nerve terminals to reduce the release of vasoactive neuropeptides. This dual action addresses both the vascular and neurogenic components of migraine pathophysiology, providing rapid symptom relief.
Approved indications
- Acute migraine with or without aura
- Cluster headache
Common side effects
- Chest pain or pressure
- Dizziness
- Somnolence
- Tingling or paresthesia
- Flushing
- Asthenia or fatigue
Key clinical trials
- A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) (PHASE3)
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) (PHASE3)
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) (PHASE3)
- Efficacy and Safety of BGG492 in the Treatment of Migraine (PHASE2)
- Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine (PHASE2)
- Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks (PHASE3)
- Treximet Early Intervention Adolescent Migraine (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: sumatriptan CI brief — competitive landscape report
- Comparator: sumatriptan updates RSS · CI watch RSS
- Organon and Co portfolio CI